BioCryst Achieves First Full Year GAAP Profitability, Reports Strong ORLADEYO Revenue Growth Amidst Key Acquisition and Patent Litigation

summarizeSummary

BioCryst Pharmaceuticals reported its first full year of GAAP profitability in 2025, driven by strong ORLADEYO revenue, while also detailing the financial impact of the Astria Therapeutics acquisition and ongoing patent litigation for ORLADEYO.

check_boxKey Events

• Achieved First Full Year GAAP Profitability

  The company reported net income of $263.861 million for the fiscal year ended December 31, 2025, marking its first full year of GAAP profitability, a significant turnaround from a net loss of $88.881 million in 2024. This confirms the preliminary announcement made in an 8-K on the same day.

• Substantial Revenue Growth

  Total revenues increased to $874.8 million in 2025 from $450.7 million in 2024, primarily driven by ORLADEYO sales, which reached $601.839 million globally. This also includes $243.3 million in license revenue from the sale of the European ORLADEYO business.

• Finalized Astria Therapeutics Acquisition and New Debt

  The acquisition of Astria Therapeutics was finalized on January 23, 2026, for cash consideration of $636.809 million and the issuance of 37.282 million shares of common stock (equity consideration of $251.656 million). A new $400 million Blackstone Loan Agreement was entered into to fund the cash portion of the acquisition.

• Patent Litigation for ORLADEYO

  The company received a Paragraph IV notice from Annora Pharma Private Limited seeking approval for a generic version of ORLADEYO, challenging four patents expiring in 2039. BioCryst has filed a patent infringement lawsuit to defend its intellectual property rights.

auto_awesomeAnalysis

This annual report confirms BioCryst Pharmaceuticals' achievement of GAAP profitability for the first time in its history for the fiscal year 2025, a significant milestone driven by robust ORLADEYO revenue growth. The filing provides comprehensive audited financial results, detailing the company's strong operational performance. However, it also outlines substantial strategic and financial developments, including the finalized acquisition of Astria Therapeutics, which involved significant equity issuance and new debt, leading to considerable potential dilution. A critical risk factor is the ongoing patent infringement litigation concerning ORLADEYO, their primary revenue driver, which could impact future commercial exclusivity. Investors should weigh the positive financial turnaround and pipeline expansion against the dilution and legal challenges to the company's key product.